Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
Mesoblast reported preliminary fiscal Q1 results with RYONCIL net revenue of $28 million, up 44% year-over-year, and September marking the highest month of new patient starts. Operating cash spend fell 86% to $2.1 million from $14.9 million a year earlier, leaving the company with $99 million in cash at quarter end. On the pipeline, all 350 patients in the pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain have completed treatment, with the 12-month durable pain reduction primary endpoint reading out next year.
Key figures
- Revenue
- 28000000
- Drug Name
- rexlemestrocel-L
- Revenue Yoy
- 44%
- Phase Of Trial
- Phase 3
- Trial size
- 350-patient Phase 3 pivotal trial of rexlemestrocel-L completed enrollment of all treatments
- Cash position
- US$99 million
- Operating cash spend
- 2100000
- Prior year operating cash spend
- 14900000
- Operating cash spend improvement
- 86%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.